HEMOGENYX PHARMACEUTICALS PLC

Board/Management Information • Nov 15, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5017W

Hemogenyx Pharmaceuticals PLC

15 November 2017

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Directorate change

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that following the successful completion of the Company's readmission and trading on the main market of the London Stock Exchange, Timothy Le Druillenec, Finance Director, has advised the Board of his intention to step down as a Director at the end of the month and will not be seeking re-election at the forthcoming annual general meeting of the Company in order to pursue other interests.

Timothy was previously Chief Financial Officer of Silver Falcon plc and the Board is in process of putting in place appropriate arrangements for the future financial management of the Company.

Dr Robin Campbell, Chairman of Hemogenyx, commented: "I would like to thank Timothy for his contribution to the Company, and in particular his support during the successful acquisition of Hemogenyx and our listing on the London Stock Exchange."

Enquiries:

Hemogenyx Pharmaceuticals Limited		www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder		Via Walbrook PR
Dr Robin Campbell, Chairman
Optiva Securities Ltd		Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP		Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited		Tel: +44 (0)20 7469 0930
Lucy Williams/Duncan Vasey
Walbrook PR	Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Paul McManus	Mob: +44 (0)7980 541 893

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAGGGBUGUPMGMC